 Sanjana Mehrotra
Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 2 | 2026 | 380 | 1.090 |
Why?
| | Thyroid Gland | 1 | 2026 | 93 | 0.920 |
Why?
| | Trans-Activators | 2 | 2026 | 398 | 0.920 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2025 | 17 | 0.870 |
Why?
| | Pancreatic Neoplasms | 5 | 2023 | 947 | 0.850 |
Why?
| | Hematologic Neoplasms | 1 | 2026 | 169 | 0.820 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2020 | 62 | 0.730 |
Why?
| | Malacoplakia | 1 | 2020 | 1 | 0.630 |
Why?
| | Biopsy, Fine-Needle | 4 | 2026 | 79 | 0.600 |
Why?
| | Carcinoma, Lobular | 4 | 2026 | 59 | 0.500 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2017 | 38 | 0.500 |
Why?
| | Kidney Neoplasms | 1 | 2020 | 421 | 0.450 |
Why?
| | Histiocytic Sarcoma | 1 | 2015 | 3 | 0.450 |
Why?
| | Cell Transdifferentiation | 1 | 2015 | 31 | 0.440 |
Why?
| | Neuroendocrine Tumors | 1 | 2017 | 123 | 0.440 |
Why?
| | Lymphoma, Follicular | 1 | 2015 | 57 | 0.430 |
Why?
| | Biomarkers, Tumor | 5 | 2025 | 1339 | 0.360 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2026 | 430 | 0.320 |
Why?
| | Cell Cycle Proteins | 2 | 2026 | 633 | 0.300 |
Why?
| | Middle Aged | 13 | 2026 | 36821 | 0.250 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2020 | 330 | 0.250 |
Why?
| | Breast Neoplasms | 5 | 2026 | 2420 | 0.230 |
Why?
| | Erythroblasts | 1 | 2025 | 18 | 0.220 |
Why?
| | Tongue Neoplasms | 1 | 2025 | 26 | 0.220 |
Why?
| | Single-Domain Antibodies | 1 | 2025 | 16 | 0.210 |
Why?
| | Salivary Gland Neoplasms | 1 | 2025 | 39 | 0.210 |
Why?
| | Diagnosis, Differential | 2 | 2020 | 1518 | 0.210 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2026 | 137 | 0.200 |
Why?
| | Aged | 9 | 2026 | 26516 | 0.200 |
Why?
| | DNA Repair | 1 | 2026 | 256 | 0.200 |
Why?
| | Immunoconjugates | 1 | 2024 | 138 | 0.190 |
Why?
| | Sarcoma | 1 | 2025 | 210 | 0.180 |
Why?
| | Vasculitis | 1 | 2023 | 69 | 0.180 |
Why?
| | Antibodies, Neutralizing | 1 | 2025 | 345 | 0.180 |
Why?
| | Cell Nucleolus | 1 | 2021 | 20 | 0.170 |
Why?
| | Genetic Testing | 1 | 2025 | 493 | 0.170 |
Why?
| | Humans | 21 | 2026 | 147306 | 0.160 |
Why?
| | Receptors, Estrogen | 3 | 2021 | 406 | 0.160 |
Why?
| | Nuclear Proteins | 1 | 2026 | 745 | 0.160 |
Why?
| | Cytodiagnosis | 1 | 2020 | 31 | 0.160 |
Why?
| | Male | 10 | 2026 | 73954 | 0.150 |
Why?
| | Female | 14 | 2026 | 80081 | 0.150 |
Why?
| | Immunotherapy | 1 | 2024 | 672 | 0.150 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2023 | 299 | 0.140 |
Why?
| | Radiosurgery | 1 | 2022 | 400 | 0.140 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 345 | 0.140 |
Why?
| | Retrospective Studies | 4 | 2026 | 17561 | 0.140 |
Why?
| | Adenocarcinoma | 2 | 2023 | 928 | 0.140 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2020 | 223 | 0.130 |
Why?
| | Urinary Tract Infections | 1 | 2020 | 212 | 0.130 |
Why?
| | Cytological Techniques | 1 | 2017 | 27 | 0.130 |
Why?
| | Carcinoma, Medullary | 1 | 2017 | 16 | 0.130 |
Why?
| | Cholestasis | 1 | 2020 | 217 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 569 | 0.130 |
Why?
| | Pseudomonas aeruginosa | 1 | 2020 | 397 | 0.120 |
Why?
| | Observer Variation | 1 | 2017 | 358 | 0.120 |
Why?
| | Adult | 8 | 2026 | 41406 | 0.120 |
Why?
| | S100 Proteins | 1 | 2015 | 35 | 0.110 |
Why?
| | Histocytochemistry | 1 | 2015 | 79 | 0.110 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 66 | 0.110 |
Why?
| | Gene Rearrangement | 1 | 2015 | 156 | 0.100 |
Why?
| | Lymph Nodes | 2 | 2015 | 514 | 0.100 |
Why?
| | Pancreas | 1 | 2017 | 345 | 0.100 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2015 | 231 | 0.100 |
Why?
| | Receptors, Cell Surface | 1 | 2015 | 373 | 0.090 |
Why?
| | Breast | 2 | 2021 | 157 | 0.090 |
Why?
| | Kidney | 1 | 2020 | 1511 | 0.090 |
Why?
| | Antigens, CD | 1 | 2015 | 562 | 0.090 |
Why?
| | Pyrazoles | 1 | 2015 | 518 | 0.080 |
Why?
| | Cyclooxygenase 2 | 2 | 2009 | 167 | 0.080 |
Why?
| | Pyridines | 1 | 2015 | 610 | 0.080 |
Why?
| | Carcinoma, Ductal, Breast | 2 | 2009 | 91 | 0.080 |
Why?
| | B-Lymphocytes | 1 | 2015 | 878 | 0.070 |
Why?
| | Neoadjuvant Therapy | 2 | 2023 | 474 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1940 | 0.070 |
Why?
| | Breast Neoplasms, Male | 1 | 2009 | 29 | 0.070 |
Why?
| | Neoplasms | 1 | 2024 | 2946 | 0.070 |
Why?
| | Young Adult | 2 | 2025 | 14437 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2026 | 3565 | 0.070 |
Why?
| | Receptors, Prostaglandin E | 1 | 2007 | 8 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3980 | 0.060 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 287 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 1195 | 0.060 |
Why?
| | Lymphangiogenesis | 1 | 2005 | 27 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1338 | 0.060 |
Why?
| | Phthalazines | 1 | 2026 | 63 | 0.060 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 61 | 0.060 |
Why?
| | Camelidae | 1 | 2025 | 1 | 0.060 |
Why?
| | Molecular Docking Simulation | 1 | 2025 | 119 | 0.050 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2025 | 377 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2025 | 325 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2005 | 288 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2026 | 939 | 0.050 |
Why?
| | Molecular Dynamics Simulation | 1 | 2025 | 268 | 0.050 |
Why?
| | CA-19-9 Antigen | 1 | 2023 | 36 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2679 | 0.040 |
Why?
| | Lung | 1 | 2015 | 4141 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8432 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2005 | 627 | 0.040 |
Why?
| | MCF-7 Cells | 1 | 2021 | 133 | 0.040 |
Why?
| | Promoter Regions, Genetic | 2 | 2021 | 1253 | 0.040 |
Why?
| | Tamoxifen | 1 | 2021 | 193 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 2020 | 252 | 0.040 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 1514 | 0.040 |
Why?
| | Microscopy, Confocal | 1 | 2020 | 322 | 0.040 |
Why?
| | Bile Duct Neoplasms | 1 | 2020 | 133 | 0.030 |
Why?
| | Cytokines | 1 | 2005 | 2087 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1059 | 0.030 |
Why?
| | Mutation | 1 | 2025 | 4130 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2021 | 2529 | 0.020 |
Why?
| | Prognosis | 2 | 2015 | 4384 | 0.020 |
Why?
| | Animals | 2 | 2026 | 38417 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 2001 | 0.020 |
Why?
| | Signal Transduction | 2 | 2021 | 5272 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2921 | 0.020 |
Why?
| | Infant | 1 | 2025 | 10195 | 0.020 |
Why?
| | Child, Preschool | 1 | 2025 | 12017 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 200 | 0.020 |
Why?
| | Mice | 1 | 2026 | 18493 | 0.020 |
Why?
| | Microcirculation | 1 | 2009 | 142 | 0.020 |
Why?
| | Receptors, Prostaglandin E, EP1 Subtype | 1 | 2007 | 2 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 11947 | 0.020 |
Why?
| | Cytoplasm | 1 | 2007 | 255 | 0.020 |
Why?
| | Receptors, Progesterone | 1 | 2007 | 244 | 0.010 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2005 | 48 | 0.010 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2005 | 95 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 980 | 0.010 |
Why?
| | Adolescent | 1 | 2025 | 22826 | 0.010 |
Why?
| | Blotting, Western | 1 | 2007 | 1186 | 0.010 |
Why?
| | Prospective Studies | 1 | 2017 | 8166 | 0.010 |
Why?
| | Child | 1 | 2025 | 22980 | 0.010 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2005 | 88 | 0.010 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2005 | 44 | 0.010 |
Why?
| | Lymphatic Metastasis | 1 | 2005 | 338 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2007 | 589 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1730 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1492 | 0.010 |
Why?
| | Tumor Suppressor Proteins | 1 | 2005 | 323 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2005 | 499 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2005 | 440 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2005 | 525 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2007 | 1457 | 0.010 |
Why?
| | Phosphorylation | 1 | 2005 | 1721 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2812 | 0.010 |
Why?
| | Biomarkers | 1 | 2005 | 4354 | 0.010 |
Why?
|
|
Mehrotra's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|